InsidersTradesSigma
Follow the Monopar Therapeutics Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €747.5m. The latest transaction was filed on 25 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Arthur Klausner. All data is accessible without an account.
Analysts rate Monopar Therapeutics Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$126.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
Monopar Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare and difficult-to-treat cancers. It employs innovative approaches to improve patient outcomes.